Company intelligence / Profile preview
Beijing Aige Stem Cell Technology
Beijing, Beijing Shi, Chinaaeglestem.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead asset—human adipose derived mesenchymal stem cells—is in Phase 1/2 clinical trials targeting systemic scleroderma. INDs have been approved for diabetic foot ulcer and localized scleroderma. No published clinical results yet available as of January–February 2025. Pipeline includes at least five preclinical programs focused on various indications related to regenerative medicine using mesenchymal stem cells.
- Therapeutic areas
- EndocrinologyImmunologyDermatologyRheumatologyCardiovascularNeurology
- Modalities
- Mesenchymal stem cell therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Beijing Aige Stem Cell Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Aige Stem Cell Technology.